O ne advantage of nanoparticles over small molecular compounds is their ability to perform multiple functions simultaneously. In particular, nanotechnology can be used to tailor treatment to individual patients by integrating diagnostic and therapeutic capabilities into a single entity. These theranostic techniques rely on the successful delivery and detection of nanoparticles at the diseased sites. Multifunctional nanomaterials that absorb light with high efficiency are especially useful for theranostic applications. These lightabsorbing agents can not only reveal the molecule-specific signatures of cancer with high sensitivity and high spatial resolution when viewed using photoacoustic imaging 1, 2 but also mediate the selective killing of cancer cells via photothermal ablation and drug release. 3 Image-guided phototherapy, especially when done in real time, allows for the optimal planning of the therapy and more accurate targeting of the treatment volume and nearby critical structures. After therapy delivery, changes in parameters such as tissue perfusion and diffusion may be used to visualize the extent of therapy and thus can be used as crucial feedback regarding the safety, efficacy, and overall outcomes of the therapy.
Gold coreÀshell nanostructures, which consist of a dielectric or semiconducting core surrounded by an ultrathin gold shell, have been shown to mediate both photodetection and phototherapy. 4, 5 Hollow gold nanospheres (HAuNS) are second-generation gold nanostructures that have the unique combination of small size (outer diameter = 30À50 nm), spherical shape, and hollow interior with a thin gold shell (3À6 nm). Various homing ligands, including aptamers, 6 peptides, 7 antibodies, 8 and small-molecularweight organic compounds, 9 have been conjugated on the surface of gold nanoshells. These homing ligands selectively direct the nanoparticles to the target sites. Aptamers consist of short DNA/RNA molecules that can bind specifically to proteins and other targets. Because of their relatively small size, high specificity, and nonimmunogenicity, they are being developed for treatment of diseases, such as cancer, HIV, heart diseases, and macular degeneration. In fact, a few aptamers are either approved by the U.S. Food and Drug Administration or are currently in clinical trials. 10 Several works based on aptamer with siRNA and nanoparticles are also currently being investigated in preclinical animal models for the treatment and imaging of cancer and HIV. 11À13 On the basis of these previous studies, we hypothesized that aptamers targeted to epidermal growth factor receptors (EGFR) are attractive homing ligands for the targeted thermal ablation of head and neck cancers.
To compare the utility of aptamers with that of currently used ligands, we evaluated the effect of conjugating aptamers versus that of conjugating an antibody on the surface of HAuNS targeted to EGFR. EGFR is overexpressed in 90% of head and neck cancers; 14À16 the mean EGFR levels in squamous cell cancer of the head and neck and normal tissue have more than 13-fold difference. 17 The selective accumulation of aptamer-and antibody-conjugated HAuNS was compared on the basis of the in vivo pharmacokinetics and biodistribution of HAuNS in tumor-bearing mice, and the increased uptake of the HAuNS conjugates was validated using single-photon emission computed tomography/computed tomography (SPECT/CT) imaging of 111 In-labeled HAuNS.
RESULTS AND DISCUSSION
Apt-HAuNS Characterization. Aptamers were conjugated to HAuNS by annealing SH-terminated singlestranded DNA to the HAuNS first and then adding the RNA targeted to EGFR, which has 22 bases complementary to the single-stranded DNA ( Figure 1A ). We found that the resulting Apt-HAuNS had a mean size of 59.6 ( 1.9 nm and a zeta potential of À51.4 ( 5.1 ( Table 1 ). The size of apt-HAuNS was comparable to that of PEG-HAuNS and C225-HAuNS, but apt-HAuNS 
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was more negatively charged than PEG-HAuNS (zeta potential = À19.0 ( 3.6) and C225-HAuNS (zeta potential = À25.0 ( 2.5). The absorption spectrum for apt-HAuNS was very similar to that of PEG-and C225-conjugated HAuNS ( Figure 1B) , with all of the HAuNS particles having maximum absorption in the nearinfrared region (∼800 nm). These results indicate that surface modification of the HAuNS with aptamer did not significantly change the optical and size properties of the HAuNS. Figure 1C shows a representative sensorgram obtained from SPR analyses of EGFR-targeting aptamer. Figure 1C ).
Quantification of the number of aptamers per particle was accomplished using gel electrophoresis ( Figure 2) . By calculating the signal intensity, we found that there was 1 pmol of RNA per 50 μL of HAuNS, which is equivalent to ∼250 molecules of aptamer/ particle. In comparison, approximately 124 C225 antibody molecules were attached in the C225-HAuNS. 8 We attributed this difference in number of ligands per particle to the smaller size of the aptamer (molecular weight = 35 kDa), which is four times smaller than C225 (molecular weight = 150 kDa).
Aptamer in apt-HAuNS was stable up to 48 h in plasma. More than 60% of intact aptamer was associated with HAuNS after 48 h incubation in 50% mouse plasma at 37°C as revealed by electrophoresis analysis (Supplementary Figure S1) . A similar finding was made in 50% human plasma.
In Vitro Cell Binding. Figure 3 shows the light-scattering, DAPI, and overlaid images of EGFR-positive OSC-19 cells incubated with apt-HAuNS, C225-HAuNS, and PEG-HAuNS. Apt-HAuNS and C225-HAuNS, both of which specifically target EGFR, exhibited a strong perinuclear signal in the cells. In contrast, few nanoparticles were seen in the cells treated with PEG-HAuNS, indicating less uptake of the nontargeted PEG-HAuNS in the cells.
Pharmacokinetics and Biodistribution of apt-HAuNS. To enable quantitative analysis, we labeled HAuNS conjugates with the gamma emitter 111 In, which has a long physical half-life (t 1/2 = 67.3 h) comparable to the circulation half-life of nanoparticles.
111
In-labeling was accomplished using 4-(aminobenzyl)diethylenetriaminepentaacetic acid thioctamide (DTPA-TA) as the radiometal chelator.
A previous study has shown that 111
In-DTPA-TA labeling on the gold surface possessed excellent in vivo stability. 18 The labeling efficiency was ∼70%, with radiochemical purities for 111 In-DTPA-apt-HAuNS, 11 In-DTPA-C225-HAuNS, and 11 In-DTPA-PEG-HAuNS greater than 95%. Figure 4 shows blood activityÀtime profiles after intravenous injection of PEG-HAuNS, apt-HAuNS, and C225-HAuNS to mice. As indicated by the solid lines up to 24 h, C225-HAuNS was cleared much slower in the initial distribution period followed by a slower elimination phase as compared to PEG-HAuNS and aptHAuNS. C225-HAuNS had almost 6-fold higher mean initial drug concentration in the blood, i.e., 59.1%ID/g, as compared to 11.6%ID/g and 9.4%ID/g for PEGHAuNS and apt-HAuNS, respectively. Pharmacokinetic parameters are presented in Table 2 . C225-HAuNS has significantly higher systemic exposure/bioavailability (AUC) as compared with PEG-HAuNS and apt-HAuNS groups. The systemic clearance (CL) of C225-HAuNS was significantly slower than that of the apt-HAuNS group, which may be interpreted as the C225-HAuNS being removed less efficiently by the cells of the reticuloendothelial system. The difference in CL also resulted in the observed differences in blood half-life and mean residence time (MRT). No significance was observed between the PEG-HAuNS and C225-HAuNS groups for T 1/2 , CL, and MRT. Also, no statistical gates at 24 h after injection was determined by ex vivo measurements of radioactivity and is presented in Table 3 . The organs that had the highest uptakes of 111 In-labeled apt-HAuNS, C225-HAuNS, and PEGHAuNS were the spleen and the liver. Uptake levels of 111 In-labeled apt-HAuNS and C225-HAuNS in the liver were significantly higher than that of PEG-HAuNS. There was also significantly higher uptake of C225-HAuNS in the spleen as compared with that of PEGHAuNS. 111 In-labeled apt-HAuNS had a significantly higher uptake value (3.34 ( 0.44%ID/g) in the tumor than did 111 In-labeled C225-HAuNS (1.62 ( 0.37%ID/g) or PEG-HAuNS (0.94 ( 0.32%ID/g). These differences were statistically significant (Tukey's test p < 0.001 and 0.001, respectively) ( Table 3) . It is not clear why there was higher blood activity for apt-HAuNS in the tumorbearing nude mice whereas in Swiss mice apt-HAuNS was cleared faster from the blood than PEG-HAuNS and C225-HAuNS. Probably there was a strain difference for pharmacokinetics of nanoparticles in mice. Nevertheless, our data suggest that the significant differences in tumor uptake values between apt-HAuNS and C225-HAuNS and between apt-HAuNS and PEGHAuNS cannot be explained by enhanced permeability and retention effect or other nonspecific tumor retention mechanisms.
In Vivo Imaging. The presence of OSC-19 tumors in the tongues of nude mice at day 10 after inoculation was confirmed by bioluminescence imaging ( Figure 5A ). μSPECT/CT images acquired at 4 and 24 h after injection of 111 In-labeled HAuNS conjugates are shown in Figure 5B . The imaging data confirmed the in vivo biodistribution data, revealing that more apt-HAuNS accumulated in the tumor than C225-HAuNS and PEG-HAuNS. Moreover, this 
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accumulation was higher at 24 h than at 4 h postinjection. The histologic results also confirmed the presence of HAuNS (shown as scattered yellow dots in the dark-field image in Figure 6 ). Apt-HAuNS, but not PEG-HAuNS, was distributed throughout the tumor matrix in the interstitial space.
Taking together pharmacokinetics, biodistribution, and imaging studies, our data support the notion that EGFR aptamer is a better tumor-homing ligand than EGFR antibody for targeted delivery of HAuNS. Clearly, additional studies in other nanoparticle systems are needed to confirm this finding. The tumor-targeting efficiency of nanoparticles is in general affected by nanoparticle size, charge, binding affinity of homing ligands to the target, and valency. Apt-HAuNS and C225-HAuNS had similar size, and both apt-HAuNS and C225-HAuNS were highly negatively charged. Therefore, size and charge are unlikely to be significant contributing factors to the differential tumor uptake between apt-HAuNS and C225-HAuNS in the current model system. Difference in blood circulation time is also not likely a contributing factor. If the enhanced permeability and retention effect, a nonspecific uptake mechanism, played a dominant role, higher tumor uptake of C225-HAuNS as compared to apt-HAuNS should be expected, as C225-HAuNS had a longer blood half-life than apt-HAuNS did.
Future 
with moderate binding affinity can be released from their first encountered cellular targets and penetrate deeper into the tumor, leading to higher tumor uptake.
CONCLUSION
In this study, we compared the pharmacokinetics, biodistribution, and imaging properties of aptamerand antibody-conjugated HAuNS and evaluated their specific targeting to EGFR-positive cells. Surface coating of HAuNS did not significantly alter the physicochemical properties or pharmacokinetics of the nanoparticles. The selectivity of apt-HAuNS toward EGFR-positive cells was shown both in vitro and in vivo and was confirmed by ex vivo microscopic evaluation. Our results indicate that aptamer directed to EGFR is a promising ligand for targeted delivery of HAuNS for selective thermal ablation of head and neck cancers overexpressing EGFR.
MATERIALS AND METHODS
Materials. Common reagents were purchased from SigmaAldrich (St. Louis, MO, USA) or Acros (Geel, Belgium) and were used as received unless otherwise specified. Methoxy-sulfohydro-PEG (SH-PEG, molecular weight 5000) was obtained from SigmaAldrich. The monoclonal anti-EGFR antibody C225 was obtained from ImClone Systems (New York, NY, USA). C225 is a chimeric humanÀmouse immunoglobulin G1 that binds EGFR with high affinity. 23, 24 Recombinant human EGFR/ErbB1 Fc chimera (rhEGF) was obtained from R&D Systems (Minneapolis, MN, USA). Tris(2-carboxyethyl)phosphine was purchased from Pierce Biotechnology (Rockford, IL, USA). NAP-5 columns were obtained from GE Healthcare (Illustra, Buckinghamshire, UK). Indium-111 chloride ( 111 InCl 3 ) was obtained from PerkinÀElmer (Waltham, MA, USA). Isoflurane was obtained from Henry Schein Animal Health (formerly Butler Animal Health Supply, Dublin, OH, USA). All the chemicals and solvents were at least American Chemical Society grade and were used without further purification.
Synthesis of HAuNS and Its Conjugates. HAuNS was synthesized according to our previously published method. 8 Briefly, cobalt nanoparticles were first synthesized by deoxygenating deionized water containing sodium borohydride (4.5 mL, 1 mol/L), sodium citrate (2.8 mL, 0.1 mol/L), and cobalt chloride (1.0 mL, 0.4 mol/L). The cobalt nanoparticle solution was then added to chloroauric acid, resulting in reduction of gold ions onto the surface of cobalt nanoparticles and oxidation of cobalt to cobalt oxide. Any remaining cobalt core was oxidized by air, producing the final product, HAuNS.
For apt-HAuNS synthesis, a 5 0 thiol-modified DNA at the C6 position (5 0 ThioMC6-D/TGGTCATGGC GGGCATTTAATTC, Integrated DNA Technologies, Coralville, IA, USA) was deprotected using tris(2-carboxyethyl)phosphine and then purified by NAP-5 columns per the manufacturer's instructions. A large volume of HAuNS (500 μL; 3.35 Â 10 12 particles/mL; 50 OD) was added to 10 μL (16 μM) of deprotected oligonucleotide in water at 80°C. The HAuNS were allowed to cool to 25°C and then centrifuged at 8000g for 10 min and washed with water twice to remove any unreacted oligonucleotide. To these DNA-coated HAuNS, 16 pmol of 2 0 -fluoropyrimidine-modified RNA, 5 0 -GGC GCU CCG ACC UUA GUC UCU GUG CCG CUA UAA UGC ACG GAU UUA AUC GCC GUA GAA AAG CAU GUC AAA GCC GGA ACC GUG UAG CAC AGC AGA GAAUUAAAUGCCCGCCAUGACCAG-3 0 (E07, 25 with underlined letters as the complementary sequence), which was kindly provided by Dr. Andrew Ellington from University of Texas in Austin, was added and annealed at 80°C for 3 min. This sample was again centrifuged at 8000g for 10 min and washed with water twice to remove any uncaptured RNA. To ensure complete coverage of gold surface, PEG-SH (MW = 5000) was added to the apt-coated HAuNS to a final concentration of 0.2 mg/mL, and the mixture was reacted for an additional 1 h. After the washing steps, the resulting apt-HAuNS was resuspended in 0.1 M phosphate-buffered saline (PBS).
C225-and PEG-conjugated HAuNS (C225-HAuNS and PEGHAuNS, respectively) were prepared according to a previously published protocol. 8 Briefly, an aqueous solution of C225 (2.5 mg; 0.017 μmol; 5 mg/mL) was first allowed to react with N-succinimydyl-S-acetylthioacetate (SATA) (0.077 mg; 0.332 μmol) Figure 6 . Representative photomicrographs of sectioned OSC-19 tumors from mice injected intravenously with apt-HAuNS or PEG-HAuNS. For histologic examination, sections were stained with hematoxylin and eosin. For dark-field imaging of the scattering signal (yellow) from HAuNS, cell nuclei were stained with DAPI (blue). Apt-HAuNS, but not PEG-HAuNS, was found distributed throughout the tumor matrix.
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at room temperature for 1 h. The resulting conjugate, C225-acetylthioacetate (C225-ATA), was purified by passing it through a gel filtration PD-10 column, and Biorad protein assay dye reagent (BioRad, Hercules, CA, USA) was used to guide the collection of antibody-containing fractions. C225-ATA was treated with hydroxylamine (50 mM; 50 μL) at room temperature for 2 h to expose the free thiol (SH) group. The reaction mixture was passed through a PD-10 column, and the resulting C225-SH was added to an aqueous solution of HAuNS (1.4 Â 10 12 particles/mL, 20 OD) for a final antibody concentration of 5 μg/mL. The suspension was stirred at room temperature for 1 h. Thereafter, PEG-SH (MW = 5000) was added to the antibody-coated HAuNS to a final concentration of 0.2 mg/mL, and the mixture was reacted for an additional 1 h to ensure that the gold surface in C225-HAuNS was completely covered with PEG. C225-HAuNS were centrifuged at 8000g for 5 min, and the resulting pellet was washed twice with deionized water to remove any unattached C225 and PEG from the supernatant. The purified product was resuspended in 0.1 mM PBS and stored at 4°C until further use. C225-HAuNS were stable in physiological buffers for at least 3 weeks at 4°C without aggregation.
Characterization of HAuNS Conjugates. The particle size was determined using dynamic light scattering at a scatter angle of 90°on a Brookhaven particle size analyzer (Holtsville, NY, USA). Ultraviolet (UV)Àvisible spectroscopy was recorded on a Beckman Coulter UVÀvisible spectrometer (Indianapolis, IN, USA).
To quantify the amount of aptamer conjugated on the surface of the HAuNS, apt-HAuNS along with control RNA samples ranging from 6 to 16 pM were loaded into a 15% denaturing PAGE gel, electrophoresed, and stained with SyBr gold according to the manufacturer's recommendation (Invitrogen, Eugene, OR, USA). The gel was imaged with a Storm Scanner (GE Life Sciences, Piscataway, NJ, USA), and free RNA in the HAuNS sample was quantified in ImageJ by taking the average intensity value within the band (after background subtraction). The control sample was used as a reference and taken to represent the total loaded RNA.
SPR binding assays were performed with a Biacore 3000 model system (GE Heathcare, Piscataway, NJ, USA) at 25°C using HBSEP running buffer (0.01 M HEPES [4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid], pH 7.4, 0.15 M NaCl, 3 mM ethylenediaminetetraacetic acid, and 0.005% [v/v] surfactant P20 solution). A CM-5 chip was successfully coated with recombinant human EGFR/ErbB1 Fc chimera using the 1-ethyl-3-(3-(dimethylamino)propyl)carbodiimide/N-hydroxysuccinimide (EDC/NHS method). The EGFR aptamer and C225 were diluted in HBSEP buffer, filtered, degassed, and injected at a flow rate of 30 μL/min as a series of eight concentrations. The injection time of aptamer and C225 in the HBSEP buffer was 7 min, followed by a 3 min dissociation period. The CM-5 chips were regenerated using a 30 s pulse of 10 mM glycine (pH 2.2) after each binding cycle. All analyzed samples and running buffer were injected to an rhEGFR-coated flow cell and uncoated reference cell. Data were evaluated using BIAevaluation software, version 3.1 (GE Heathcare). The obtained sensorgrams were fitted globally over the whole range of injected concentrations and simultaneously over the association and dissociation phases. Equilibrium dissociation constants were then calculated from the rate constants
Radiolabeling. InCl 3 and reacting for 30 min at room temperature. DTPA-TA was synthesized according to previously reported procedures. 18 Radiolabeling of apt-HAuNS, C225-HAuNS, and PEG-HAuNS was achieved by mixing aliquots of each nanoparticle preparation with 111 In-chelate and rotating it overnight at 4°C. The next day, 0.2 μg/mL of PEG-SH was added to the solution, which was then rotated for an additional 2 h to stabilize the radiolabeled HAuNS conjugates. Unlabeled 111 In and 111 In-DTPA-aptamer and -antibody were removed by centrifugation and washing steps. The radiolabeled nanoparticles were analyzed using an instant thinlayer chromatography strip developed with PBS (pH 7.4) containing 4 mM ethylenediaminetetraacetic acid. The data were quantified using a Bioscan IAR-2000 TLC scanner (Washington, DC, USA). Free 111 In 3þ ions moved to the solvent front (R f = 0.9), and the nanoparticles remained in their original location (R f = 0.0).
In Vitro Cell Binding. The EGFR-positive oral squamous cell carcinoma cell line OSC-19 26, 27 was kindly provided by Dr. Jeffrey Myers (The University of Texas MD Anderson Cancer Center). OSC-19 cells were maintained at 37°C in a humidified atmosphere containing 5% CO 2 in Dulbecco's modified Eagle's medium and nutrient mixture F-12 Ham containing 10% fetal bovine serum (Invitrogen, Grand Island, NY, USA).
For microscopic imaging to assess in vitro binding, OSC-19 cells were seeded onto an eight-well Lab-Tek II chamber slide (10 000 cells/well) (Thermo Scientific, Rochester, NY, USA). After 24 h, the cells were washed three times with Hank's balanced salt solution and incubated with apt-HAuNS, C225-HAuNS, and PEG-HAuNS (100 μL, 1 Â 10 11 particles/mL) at 37°C for 1 h. Thereafter, the cells were washed three times with Hank's balanced salt solution and fixed with 70% ethanol for 30 min. The cell nuclei were stained with 4 0 ,6 0 -diamidino-2-phenylindole (DAPI) for 5 min. Cells were then washed three times with PBS, mounted, and examined under a Zeiss Axio Observer.Z1 fluorescence microscope (Carl Zeiss MicroImaging GmbH, Göttingen, Germany). HAuNS were examined under a dark-field condenser illuminated by a halogen light source, and the fluorescence of the cell nuclei was detected with a Chroma DAPI filter (Chroma Technology Corp., Bellows Falls, VT, USA) illuminated by a Xenon XBO light source (OSRAM GmbH, Augsburg, Germany). The images were collected using a Hamamatsu B/W chilled charge-coupled camera (Hamamatsu Photonics K. K., Hamamatsu City, Japan) and processed using Image-Pro Plus 4.5.1 software (Media Cybernetics, Inc., Bethesda, MD, USA). The dark-field condenser allows imaging scattered light from HAuNS.
Pharmacokinetic Study. All animal studies were carried out in the Small Animal Imaging Facility at MD Anderson Cancer Center in accordance with institutional guidelines and approved by the IACUC. For the pharmacokinetic study, healthy male Swiss mice (22À25 g; Charles River Laboratories, Wilmington, MA, USA) (n = 4À5/group) were injected intravenously with 111 In-labeled apt-HAuNS and PEG-HAuNS at a dose of 7.3 Â 10 11 particles/mouse (1.4 mg HAuNS/kg body weight; 10 OD HAuNS; 30 μCi/mouse; 200 μL/mouse). At predetermined intervals (0 min, 15 min, 30 min, 45 min, 1 h, 2 h, 4 h, 6 h, and 24 h), blood samples (10 μL) were taken from the tail vein, and the radioactivity of each sample was measured with a Cobra Autogamma counter (Packard, Downers Grove, IL, USA).
All pharmacokinetic analyses were made using classical techniques and the microcomputer-based program Phoenix WinNonlin 6.3 software (Pharsight Corp., St. Louis, MO, USA). The HAuNS blood concentrationÀtime data were interpreted by noncompartmental methods. The total area under the blood concentrationÀtime curve (AUC 0-¥ ) and the area under the first moment of the blood concentrationÀtime curve (AUMC) were estimated by the trapezoidal rule with extrapolation of the terminal portion to infinity. The rate constant (K) governing the terminal elimination of the gold nanoparticles from the body was determined from the least-squares slope of the terminal linear segment of a semiloarithmic plot of blood gold nanoparticle concentration versus time. The elimination half-life (T 1/2 ) was calculated as 0.693/K. The systemic clearance was determined from dose/AUC. The volume of distribution at steady state was calculated using the following formula: Dose/[(AUMC)/(AUC 2 )]. The mean residence time was calculated from AUMC/AUC. Statistical analyses were conducted using SYSTAT 11 (SYSTAT Inc., Evanston, IL, USA). Prior to the application of any statistical test, the Levene's test for equality of variance was performed on the variances of the observations in the individual nanoparticle groups. Since we found that all the data from the three groups was homogeneous, the analysis of variance (ANOVA) followed by post hoc Tukey's test was used to determine the statistical significance among the groups. A p-value of less than 0.05 was considered as statistically significant.

